AI Engines For more Details: Perplexity Kagi Labs You
Cardiac Effects: Xamoterol acts as a selective beta-1 adrenergic receptor agonist, meaning it primarily affects the beta-1 receptors in the heart. By stimulating these receptors, xamoterol increases the strength and efficiency of heart muscle contractions, leading to improved cardiac output and blood flow.
Treatment of Heart Failure: Xamoterol is indicated for the management of chronic heart failure, a condition characterized by the heart's inability to pump blood effectively. By enhancing cardiac contractility, xamoterol helps alleviate symptoms such as shortness of breath, fatigue, and fluid retention associated with heart failure.
Beta-Blocking Activity: Despite its beta-adrenergic agonist activity, xamoterol also exhibits some degree of beta-blocking (antagonistic) effects, particularly at higher doses. This dual mechanism of action helps to improve heart function while minimizing the risk of excessive sympathetic stimulation, which can exacerbate heart failure.
Reduction of Heart Rate: Xamoterol may decrease heart rate by inhibiting the effects of sympathetic nervous system activity on the heart. This effect can be beneficial in certain patients with heart failure who have elevated resting heart rates.
Vasodilation: Xamoterol has vasodilatory properties, meaning it relaxes and widens blood vessels. This vasodilation reduces peripheral resistance to blood flow, easing the workload on the heart and improving overall cardiovascular function.
Adverse Effects: Like all medications, xamoterol can cause side effects. Common side effects may include dizziness, headache, fatigue, nausea, and gastrointestinal disturbances. Some patients may experience bradycardia (slow heart rate) or hypotension (low blood pressure) as a result of xamoterol therapy.
Contraindications: Xamoterol is contraindicated in patients with certain cardiac conditions, including severe bradycardia, heart block, cardiogenic shock, and decompensated heart failure requiring intravenous inotropic therapy. It should not be used in patients with a history of bronchospasm or asthma due to its beta-adrenergic effects.
Monitoring: Patients receiving xamoterol therapy should be closely monitored for signs of worsening heart failure, electrolyte imbalances, and adverse drug reactions. Dosage adjustments may be necessary based on individual patient response and tolerance.
Interactions: Xamoterol may interact with other medications, particularly other cardiovascular drugs such as beta-blockers, calcium channel blockers, and antiarrhythmics. Combining xamoterol with these medications can potentiate or attenuate their effects, so careful monitoring is essential.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Anaerobutyricum hallii | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Veillonella atypica | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Agathobacter | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Agathobacter rectalis | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
0 | 1 | Veillonella rodentium | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
0 | 1 | Veillonella dispar | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Bifidobacterium angulatum | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
0 | 1 | Veillonella nakazawae | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
0 | 1 | Coprobacter secundus | species | Decreases |
0 | 1 | Actinomyces naeslundii | species | Decreases |
0 | 1 | uncultured Alistipes sp. | species | Decreases |
0 | 1 | Barnesiella viscericola | species | Decreases |
0 | 1 | Butyricimonas virosa | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Alistipes megaguti | species | Decreases |
0 | 1 | Anaerobutyricum hallii | species | Decreases |
0 | 1 | Veillonella rogosae | species | Decreases |
0 | 1 | Bifidobacterium breve | species | Decreases |
0 | 1 | Fannyhessea vaginae | species | Decreases |
0 | 1 | Dorea longicatena | species | Decreases |
0 | 1 | Olsenella sp. oral taxon 807 | species | Decreases |
0 | 1 | Blautia sp. SC05B48 | species | Decreases |
0 | 1 | Wansuia hejianensis | species | Decreases |
0 | 1 | Ruminococcus albus | species | Decreases |
0 | 1 | Coprobacter fastidiosus | species | Decreases |
0 | 1 | Adlercreutzia equolifaciens | species | Decreases |
0 | 1 | Eubacterium ventriosum | species | Decreases |
0 | 1 | Alistipes sp. dk3624 | species | Decreases |
0 | 1 | Butyrivibrio crossotus | species | Decreases |
0 | 1 | Eggerthella guodeyinii | species | Decreases |
0 | 1 | Roseburia rectibacter | species | Decreases |
0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
0 | 1 | Parolsenella catena | species | Decreases |
0 | 1 | Coprococcus comes | species | Decreases |
0 | 1 | Komagataeibacter oboediens | species | Decreases |
0 | 1 | Alistipes senegalensis | species | Decreases |
0 | 1 | Alistipes ihumii | species | Decreases |
0 | 1 | Ligilactobacillus ruminis | species | Decreases |
0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
0 | 1 | Alistipes finegoldii | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
0 | 1 | Alistipes dispar | species | Decreases |
0 | 1 | Wujia chipingensis | species | Decreases |
0 | 1 | Alistipes shahii | species | Decreases |
0 | 1 | Alistipes communis | species | Decreases |
0 | 1 | Faecalibacillus intestinalis | species | Decreases |
0 | 1 | Alistipes onderdonkii | species | Decreases |
0 | 1 | Intestinibaculum porci | species | Decreases |
0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
0 | 1 | Subdoligranulum variabile | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Actinomyces oris | species | Decreases |
0 | 1 | Phoenicibacter congonensis | species | Decreases |
0 | 1 | Clostridium sp. SY8519 | species | Decreases |
0 | 1 | Veillonella atypica | species | Decreases |
0 | 1 | Clostridium sp. M62/1 | species | Decreases |
0 | 1 | Actinomyces sp. oral taxon 171 | species | Decreases |
0 | 1 | Bacillus paralicheniformis | species | Decreases |
0 | 1 | Simiaoa sunii | species | Decreases |
0 | 1 | Coprococcus eutactus | species | Decreases |
0 | 1 | Parolsenella massiliensis | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
Acne | 0.2 | -0.2 | |
ADHD | 2.2 | 0.4 | 4.5 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
Allergic Rhinitis (Hay Fever) | 1 | 1.4 | -0.4 |
Allergies | 3.7 | 2.3 | 0.61 |
Allergy to milk products | 1.1 | 0.6 | 0.83 |
Alopecia (Hair Loss) | 0.7 | 0.7 | |
Alzheimer's disease | 2.8 | 3.8 | -0.36 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.8 | 1 |
Ankylosing spondylitis | 1.8 | 0.6 | 2 |
Anorexia Nervosa | 0.8 | 1.6 | -1 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 2.6 | 1.7 | 0.53 |
Atherosclerosis | 1.2 | 1.2 | 0 |
Atrial fibrillation | 1.8 | 0.8 | 1.25 |
Autism | 3.7 | 4.2 | -0.14 |
Autoimmune Disease | 0.3 | 0.4 | -0.33 |
Barrett esophagus cancer | 0.2 | 0.2 | |
benign prostatic hyperplasia | 0.1 | 0.1 | 0 |
Biofilm | 0.4 | 0.4 | |
Bipolar Disorder | 0.7 | 0.9 | -0.29 |
Brain Trauma | 0.4 | 0.9 | -1.25 |
Breast Cancer | 0.2 | 0.2 | |
Cancer (General) | 0.5 | 1.4 | -1.8 |
Carcinoma | 1.9 | 1.6 | 0.19 |
Celiac Disease | 1.4 | 2.3 | -0.64 |
Cerebral Palsy | 0.7 | 0.9 | -0.29 |
Chronic Fatigue Syndrome | 2.7 | 3.7 | -0.37 |
Chronic Kidney Disease | 1.8 | 1.2 | 0.5 |
Chronic Lyme | 0.2 | 0.3 | -0.5 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.6 | -0.5 |
Chronic Urticaria (Hives) | 0.5 | 0.4 | 0.25 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.8 | -3 |
Cognitive Function | 1.1 | 0.7 | 0.57 |
Colorectal Cancer | 2.1 | 1.2 | 0.75 |
Constipation | 0.7 | 0.5 | 0.4 |
Coronary artery disease | 1 | 1.6 | -0.6 |
COVID-19 | 5.7 | 7.9 | -0.39 |
Crohn's Disease | 2.8 | 3.3 | -0.18 |
Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
cystic fibrosis | 0.2 | 1.3 | -5.5 |
d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
deep vein thrombosis | 0.5 | 0.7 | -0.4 |
Denture Wearers Oral Shifts | 0.5 | 0.5 | |
Depression | 4.5 | 5 | -0.11 |
Dermatomyositis | 0.2 | -0.2 | |
Eczema | 0.3 | 0.8 | -1.67 |
Endometriosis | 1.1 | 1.3 | -0.18 |
Eosinophilic Esophagitis | 0 | 0.2 | 0 |
Epilepsy | 1.4 | 1 | 0.4 |
erectile dysfunction | 0.3 | 0.2 | 0.5 |
Fibromyalgia | 1.5 | 0.5 | 2 |
Functional constipation / chronic idiopathic constipation | 2.2 | 1.9 | 0.16 |
gallstone disease (gsd) | 1.4 | 0.6 | 1.33 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 1 | -1.5 |
Generalized anxiety disorder | 0.9 | 0.9 | 0 |
giant cell arteritis | 0 | 0 | |
Gout | 1.6 | 0.2 | 7 |
Graves' disease | 1.1 | 1.8 | -0.64 |
Gulf War Syndrome | 0.3 | 0.9 | -2 |
Halitosis | 0.4 | 0.4 | |
Hashimoto's thyroiditis | 2.1 | 0.8 | 1.63 |
Heart Failure | 1.2 | 1.6 | -0.33 |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.3 | 0.2 | 0.5 |
High Histamine/low DAO | 0.4 | 0.5 | -0.25 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.3 | 0.67 |
hyperglycemia | 0.7 | 1 | -0.43 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0.2 | 1.5 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 2.1 | 3.6 | -0.71 |
Hypothyroidism | 0.1 | 0.6 | -5 |
Hypoxia | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 0.6 | 2 | -2.33 |
Inflammatory Bowel Disease | 3.3 | 5.9 | -0.79 |
Insomnia | 1 | 1.9 | -0.9 |
Intelligence | 0.5 | 0 | 0 |
Intracranial aneurysms | 0.8 | 0.2 | 3 |
Irritable Bowel Syndrome | 3.9 | 2.1 | 0.86 |
ischemic stroke | 1.7 | 0.6 | 1.83 |
Liver Cirrhosis | 3.7 | 2 | 0.85 |
Long COVID | 3.3 | 5.4 | -0.64 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.4 | 1.4 | -2.5 |
Lymphoma | 0.1 | 0.1 | |
Mast Cell Issues / mastitis | 0.1 | 0.5 | -4 |
ME/CFS with IBS | 0 | 1.9 | 0 |
ME/CFS without IBS | 0.6 | 1.2 | -1 |
Menopause | 1.3 | 0.5 | 1.6 |
Metabolic Syndrome | 3.3 | 4.1 | -0.24 |
Mood Disorders | 4.8 | 3.8 | 0.26 |
multiple chemical sensitivity [MCS] | 0.4 | 0.3 | 0.33 |
Multiple Sclerosis | 2.9 | 2.5 | 0.16 |
Multiple system atrophy (MSA) | 1.1 | 0.8 | 0.38 |
myasthenia gravis | 0.1 | 0.2 | -1 |
neuropathic pain | 0.2 | 1.9 | -8.5 |
Neuropathy (all types) | 0.6 | 0.8 | -0.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.7 | 3.7 | -0.37 |
NonCeliac Gluten Sensitivity | 1.2 | 0.4 | 2 |
Obesity | 5.7 | 3.7 | 0.54 |
obsessive-compulsive disorder | 2.6 | 1.7 | 0.53 |
Osteoarthritis | 1.1 | 0.8 | 0.38 |
Osteoporosis | 1.1 | 1.1 | 0 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 4.4 | 3.2 | 0.38 |
Polycystic ovary syndrome | 2.5 | 2.2 | 0.14 |
Postural orthostatic tachycardia syndrome | 0 | 0.2 | 0 |
Premenstrual dysphoric disorder | 0.6 | 0.6 | |
primary biliary cholangitis | 0.5 | 0.2 | 1.5 |
Primary sclerosing cholangitis | 1 | 1.3 | -0.3 |
Psoriasis | 2.2 | 1 | 1.2 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 2.2 | 0.86 |
Rosacea | 0.7 | 0.2 | 2.5 |
Schizophrenia | 3.7 | 1.7 | 1.18 |
scoliosis | 0.3 | 0.6 | -1 |
sensorineural hearing loss | 0.1 | 0.1 | |
Sjögren syndrome | 1.4 | 1.5 | -0.07 |
Sleep Apnea | 1.1 | 0.8 | 0.38 |
Slow gastric motility / Gastroparesis | 0.8 | 0.2 | 3 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.4 | 0.5 |
Stress / posttraumatic stress disorder | 1.1 | 1.3 | -0.18 |
Systemic Lupus Erythematosus | 1.3 | 1.5 | -0.15 |
Tic Disorder | 0.6 | 0.8 | -0.33 |
Tourette syndrome | 0.4 | 0.1 | 3 |
Type 1 Diabetes | 1.6 | 2.1 | -0.31 |
Type 2 Diabetes | 3.5 | 3.1 | 0.13 |
Ulcerative colitis | 2 | 3.1 | -0.55 |
Unhealthy Ageing | 1.2 | 1.3 | -0.08 |
Vitiligo | 0.9 | 0.6 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]